ArticleCell chemical biology2018
Repurposing HAMI3379 to Block GPR17 and Promote Rodent and Human Oligodendrocyte Differentiation.
Open access · bronzeAbstract read
In one paragraph
Article in Cell chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Review
- Discovery of novel and selective GPR17 antagonists as pharmacological tools for developing new therapeutic strategies in diabetes and obesity.European journal of medicinal chemistry · 2025Article
- Leukotrienes: Bridging the Inflammatory Gap in Asthma and Inflammatory Bowel Diseases (IBD).Comprehensive Physiology · 2025Review
- Inosine Treatment Attenuates White Matter Injury in Neonatal Rats Exposed to Maternal Inflammation.Neurochemical research · 2025Article
- G Protein-Coupled Receptor 17 Inhibits Glucagon-like Peptide-1 Secretion via a Gi/o-Dependent Mechanism in Enteroendocrine Cells.Biomolecules · 2024Article
- G protein-coupled receptor 17 inhibits glucagon-like peptide-1 secretion via a Gi/o-dependent mechanism in enteroendocrine cells.bioRxiv : the preprint server for biology · 2024Article
- GPR17 modulates anxiety-like behaviorsActa pharmaceutica Sinica. B · 2024Article
- Necrostatin-1s Suppresses RIPK1-driven Necroptosis and Inflammation in Periventricular Leukomalacia Neonatal Mice.Neurochemical research · 2024Article
- Neuronal ambient RNA contamination causes misinterpreted and masked cell types in brain single-nuclei datasets.Neuron · 2022Article
- The landscape of targets and lead molecules for remyelination.Nature chemical biology · 2022Review
- Activation of AExperimental and therapeutic medicine · 2022Article
- The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?International journal of molecular sciences · 2022Review
- Intestinal Gpr17 deficiency improves glucose metabolism by promoting GLP-1 secretion.Cell reports · 2022Article
- Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents.Molecular diversity · 2021Article
- Oligodendrocyte Dysfunction in Amyotrophic Lateral Sclerosis: Mechanisms and Therapeutic Perspectives.Cells · 2021Review
- Oligodendrocyte Development and Implication in Perinatal White Matter Injury.Frontiers in cellular neuroscience · 2021Review
- Abnormal Upregulation of GPR17 Receptor Contributes to Oligodendrocyte Dysfunction in SOD1 G93A Mice.International journal of molecular sciences · 2020Article
- Strategies for Oligodendrocyte and Myelin Repair in Traumatic CNS Injury.Frontiers in cellular neuroscience · 2020Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 3 countries.
Nicole MertenMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany.
Julia FischerInstitute of Reconstructive Neurobiology, LIFE&BRAIN Center, University of Bonn, 53105 Bonn, Germany.
Katharina SimonMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany.
Liguo ZhangDepartment of Pediatrics, Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA.
Ralf SchröderMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany.
Lucas PetersMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany.
Anne-Gaelle LetombeUCB Biopharma, CNS Research, 1420 Braine-l'Alleud, Belgium.
Stephanie HennenMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany.
Ramona SchrageUCB Biopharma, CNS Research, 1420 Braine-l'Alleud, Belgium.
Theresa BödefeldPharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn, 53115 Bonn, Germany.
Celine VermeirenUCB Biopharma, CNS Research, 1420 Braine-l'Alleud, Belgium.
Michel GillardUCB Biopharma, CNS Research, 1420 Braine-l'Alleud, Belgium.
Klaus MohrPharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn, 53115 Bonn, Germany.
Qing Richard LuDepartment of Pediatrics, Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA.
Oliver BrüstleInstitute of Reconstructive Neurobiology, LIFE&BRAIN Center, University of Bonn, 53105 Bonn, Germany.
Jesus GomezaMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany. Electronic address: jgomeza@uni-bonn.de.
Evi KostenisMolecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany. Electronic address: kostenis@uni-bonn.de.
University of Bonn · DEUCB Pharma (Belgium) · BECincinnati Children's Hospital Medical Center · US
Funding
Molecular Mechanisms of Oligodendrocyte Differentiation and MyelinationR01NS072427 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI LU, QING R · 2010 to 2018
$3.6MChromatin remodeling control of myelination and remyelinationR01NS075243 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI LU, QING R · 2012 to 2018
$2.6MMolecular and signaling mechanisms of peripheral nerve sheath tumorigenesisR37NS096359 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI LU, QING R · 2016 to 2018
$1.6MNINDS NIH HHS R01 NS072427NINDS NIH HHS R01 NS075243NINDS NIH HHS R37 NS096359
Abstract
Identification of additional uses for existing drugs is a hot topic in drug discovery and a viable alternative to de novo drug development. HAMI3379 is known as an antagonist of the cysteinyl-leukotriene CysLT
Indexed as
Drug RepositioningAnimalsCell DifferentiationCyclohexanecarboxylic AcidsDose-Response Relationship, DrugHumansIndolesMiceMice, KnockoutMolecular StructureOligodendrogliaPhthalic AcidsPropionatesRatsReceptors, G-Protein-CoupledStructure-Activity Relationship2-carboxy-4,6-dichloro-(1H)-indole-3-propanoic acid3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-(cyclohexyloxy)butoxy)phenyl)propoxy)benzoic acidCyclohexanecarboxylic AcidsGPR17 protein, humanIndolesPhthalic AcidsPropionatesReceptors, G-Protein-Coupleddemyelinating diseasedrug repurposingGPCRGPR17G protein-coupled receptorHAMI3379label-free dynamic mass redistributionoligodendrocyteorphan GPCRsignal transduction
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.